Myeloma News and Research

RSS

Carfilzomib therapy shows promise for pre-kidney transplant patients

Early findings by researchers at the University of Cincinnati College of Medicine suggest that the use of a second generation cancer drug, carfilzomib, may provide an improved approach for the reduction of antibodies in potential kidney transplant candidates.

10 Jun 2016

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD.

10 Jun 2016

Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Scientists have discovered unexpected functions of small nucleolar RNAs (snoRNAs) that explain the cause of some diseases.

7 Jun 2016

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

6 Jun 2016

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

18 May 2016

Novel animal model helps understand mechanisms that lead to multiple myeloma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. The study was published in the journal Scientific Reports.

6 May 2016

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.

30 Apr 2016

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.

29 Apr 2016

Residential radon exposure may lead to hematologic cancer risk in women

A new report finds a statistically-significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study of residential radon exposure and hematologic cancer risk, leading the authors to caution that it requires replication to better understand the association and whether it truly differs by sex. It appears early online in Environmental Research.

29 Apr 2016

Series of routine tests may not be beneficial to patients with age-related disorder

A series of tests physicians routinely order to help diagnose and follow their patients with an elevated antibody level that is a marker for cancer risk, often do not benefit the patient but do increase health care costs, pathologists report.

27 Apr 2016

Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

New knowledge about the mechanism of specific protein complexes in the body could help in the development of better drugs for the treatment of diseases such as cancer and Alzheimer’s, according to research led by the University of Leicester.

25 Apr 2016

Rab inhibition may be a promising antimyeloma strategy

Roswell Park Cancer Institute researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. The results will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.

22 Apr 2016

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

Multiple myeloma (MM) is a hematological cancer that frequently acquires resistance to chemotherapeutic drugs. Additionally, many patients experience disease relapse, but these patients are difficult to treat as the cancer is often resistant to the previous treatment regimen.

22 Apr 2016

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.

21 Apr 2016

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans.

21 Apr 2016

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment.

21 Apr 2016

Radiotherapy needs likely to increase in all European countries by 2025

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.

19 Apr 2016

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

18 Apr 2016

Myeloma News and Research

Carfilzomib therapy shows promise for pre-kidney transplant patients

Researchers discover AF1q protein linked to multiple myeloma, EMD

Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Novel animal model helps understand mechanisms that lead to multiple myeloma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

Residential radon exposure may lead to hematologic cancer risk in women

Series of routine tests may not be beneficial to patients with age-related disorder

Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

Rab inhibition may be a promising antimyeloma strategy

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

BCR-ABL halving time indicates CML prognosis during front-line TKI

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

Imatinib-related symptom burden linked to adherence in Indian CML patients

Radiotherapy needs likely to increase in all European countries by 2025

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News